Irvine, California, United States – 09/07/2021 — Patent protects methods and devices for customized real time treatment of chronic inflammation related disorders with bioelectric stimulation based protein expressions and control
Irvine, California —(PRDistribution)- Leonhardt Ventures LLC, a clinical stage innovation development and venture creation firm, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,110,274 titled “System and Method of Treating Inflammation.” Click here for link to published patent > https://patents.justia.com/patent/11110274
“We believe this to be the first patented device and method for precise customization of inflammation treatment. This is accomplished by first reading inflammation levels and then adjusting precise bioelectric signaling sequences to control specific anti-inflammatory cytokine expressions – at just the right time in the healing cycle,” states Howard J. Leonhardt, Inventor, Executive Chairman, and CEO of Leonhardt Ventures LLC. “In our scientific team’s opinion, previous inflammation treatments that attempted to deliver one single molecule, cytokine, or signal in a standardized dose for all patients with varying levels of inflammation failed to modulate inflammation properly. We believe that personalizing treatment based on a patient’s real-time inflammation level and then stimulating customized cytokine expressions at the proper timing is a better path will achieve the best outcomes.”
The ’274 patent with 15 patent claims issued becomes the nineteenth patent or patent pending of the Leonhardt IP estate related to bioelectric and biologics based organ regeneration and recovery.
Claim 1 of 15 of ‘274 issued patent:
A device that determines a subject’s level of inflammation following organ and/or tissue injury in the subject and then, in response to said determination, is programmed to provide at least one bioelectric signal to tissue of the subject so as to regulate expression of selected protein(s) by the tissue, so as to balance inflammation in the subject for organ and/or tissue healing and recovery in the subject, wherein the device comprises: wherein the applied bioelectric signal(s) influence expression of protein(s) in the tissue of the subject to which a bioelectric signal or signals is applied.
sensor(s) for determining the subject’s level of inflammation;
a microprocessor that, based upon the subject’s level of inflammation, is programmed to provide at least one bioelectric signal in order to balance inflammation in the subject; and
electrode(s) for applying bioelectric signal(s) to tissue of the subject,
Chronic inflammatory related diseases are amongst the most significant causes of death in the world. Research is building that suggests chronic inflammation plays a significant role in almost all disease and illness, including diabetes, cardiovascular diseases, arthritis, and joint diseases, Chronic Obstructive Pulmonary Disease (COPD), allergies, asthma, kidney disease, obesity, cancer, depression, dementia, anxiety, COVID coronavirus, Parkinson’s, Alzheimer’s disease and autoimmune diseases of all types, including Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.
Chronic inflammation occurs when the inflammation response goes overboard when dealing with a small problem often as small as a minor cut, injury or burn.
“There is a significant unmet medical need to find new ways to treat chronic inflammation-related disease progression in patients whose inflammation is inadequately controlled with conventional biologic or drug therapies,” said Leslie Miller, MD, Chief Medical Officer of Leonhardt Ventures LLC and Leonhardt’s Launchpads innovation accelerator. “Our team looks forward to gathering additional statistically significant supporting data for this therapeutic candidate in well designed studies forward. We in particular have great excitement about applying this technology to potentially helping severe heart failure patients to recover where we believe chronic inflammation is a major contributing factor.”
Leonhardt’s Launchpads the innovation and startup launch accelerator arm of Leonhardt Ventures LLC has a full portfolio https://leonhardtventures.com/development-pipeline/ of innovation assets that will likely employ this patented inflammation treatment technology platform. The business model of this innovation accelerator is to help accelerate the pathway of organ or purpose specific applications of Leonhardt core IP through first in human studies and then secure a strategic partner/acquirer to advance that organ specific application through to commercialization.
This newly issued inflammation modulation patent complements well our previous patent filing for bioelectric klotho modulation a highly potent inflammation modulating circulating protein https://patents.justia.com/patent/20200289826
Leonhardt’s Launchpads sponsored lab and clinical studies have demonstrated an ability to increase circulating klotho from 150% to up to 5X via bioelectric stimulation of skeletal muscle or over and under the kidneys or both.
A Leonhardt Ventures LLC innovation development team is working on BodStim www.bodstim.com a wearable bioelectric body suit currently in early stage evaluation and study that is intended in the future to be a possible option for increasing circulating klotho levels, once proven to be safe and effective.
Another Leonhardt Ventures LLC startup unit KlothoBios recently launched the KlothoYears www.klothoyears.com blood test kit for measuring circulating klotho levels and reporting how they stand in relation to similar aged peers working in collaboration with known experienced test assay suppliers and a qualified laboratory in San Diego.
This inflammation treatment device and method is in early stages of development and is not yet proven to be either safe or effective. Significant technological hurdles exist to perfect the device as originally intended as described in this issued patent especially accurate real time reads of inflammation. Our team is working to partner with other firms focusing on rapid analysis of inflammation to combine with our bioelectric protein expression technology platform that is more advanced in development.
About Leonhardt Ventures LLC: Since 1982 the Leonhardt team has worked on innovations in medtech. In the 1980’s the team patented, developed and brought to market the PolyCath TM line of cardiovascular balloon catheters. In the 1990’s StentValve one of the first percutaneous delivered heart valves and TALENT (Taheri-Leonhardt) aortic aneurysm stent grafts. Since 2000 the team has focused primarily on the convergence of bioelectrics and biologics for organ regeneration and healing. In 2001 Leonhardt led a team that competed the first non-surgical repair of a human heart with muscle stem cells in The Netherlands. See www.leonhardtventures.com and www.calxstars.com for more information. As part of the Master IP Agreement https://leonhardtventures.com/wp-content/uploads/2021/01/MasterPatentIPLicenseandDevelopmentAgreementVer2.0.pdf between Leonhardt Ventures LLC and the innovation and startup launch accelerator all organ or purpose specific innovation assets and corresponding startups receive exclusivity to this IP for their charter application purpose ie; LiverCell LTP www.livercellstim.com has all Leonhardt IP rights for liver regeneration and recovery as long as Leonhardt Ventures LLC’s non-dilutive equity position is maintained. Leonhardt’s Launchpads has R&D labs in California and Utah at this time and has collaborative researchers and suppliers around the globe. Over 700 patent claims have been issued, optioned, licensed or are in process related to organ regeneration and recovery – https://patents.justia.com/inventor/howard-j-leonhardt
Warnings and Disclaimers: Patents pending may not be issued. Patents issued, licensed or optioned may not be maintained. Products are early stage in development and are not yet proven safe or effective. Company lacks sufficient resources to bring these products through development and certainly fully to commercialization. As an investment these early stage innovation assets and startups have to be regarded in the highest risk category for total loss. The product development teams are attempting to achieve organ regeneration thresholds never before reached by any other group including those with substantially greater resources. A small core team is working on many developments and may not have the sufficient time to properly develop each innovation through first in human studies as planned. Forward looking statements are subject to change without notice. Any timelines, implied or quoted, are highly subject to change even by many years. Current bench top stimulator Model 240 FDA 510K market clearance working with Mettler Electronics of Anaheim, California is only for improving blood circulation, muscle injury recovery and muscle spasms treatment, deep vein thrombosis prevention following surgery, arthritis/joint pain treatment and mild pain relief.